July 26, 2014 7:47 AM ET


Company Overview of Boston Therapeutics, Inc.

Company Overview

Boston Therapeutics, Inc. focuses on the development, manufacture, and commercialization of therapeutic drugs based on complex carbohydrate chemistry to address unmet medical needs in diabetes and inflammatory diseases. It offers SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. The company’s product pipeline includes BTI-320, a non-systemic chewable therapeutic compound, which has completed a Phase II clinical trial to reduce post-meal glucose elevation; IPOXYN, an injectable anti-necrosis drug candidate for the treatment of lower limb ischemia associated with diabetes; and OxyFex for use as an oxygen delivery agent in ve...

1750 Elm Street

Suite 103

Manchester, NH 03104

United States

Founded in 2009

8 Employees





Key Executives for Boston Therapeutics, Inc.

Age: 60
Total Annual Compensation: $71.7K
Chief Financial Officer
Age: 71
Total Annual Compensation: $68.1K
Compensation as of Fiscal Year 2013.

Boston Therapeutics, Inc. Key Developments

Boston Therapeutics, Inc. Appoints Benjamin Rivnay as Chief Scientist

Boston Therapeutics, Inc. has appointed Benjamin Rivnay, Ph.D. to serve as its Chief Scientist, a newly created position. In this role, Dr. Rivnay will be responsible for the development of the company's science and technology. He will serve as the primary liaison to the company's Medical Advisory Board and report to Rom E. Eliaz, Ph.D., chairman of the board of directors Scientific Advisory Committee. Dr. Rivnay is a seasoned director of technology and research activities within the biotechnology industry. Most recently, he was Director of Research and Development at Formatech Inc.

Kenneth A. Tassey, Jr. Resigns as President and Director of Boston Therapeutics, Inc

Effective as of June 30, 2014, Kenneth A. Tassey, Jr. resigned as President and a director of Boston Therapeutics, Inc. Mr. Tassey's resignation was not the result of any disagreements with the company regarding its operations, policies, or practices.

Boston Therapeutics Initiates Phase IIb Study to Assess the Efficacy and Safety of SUGARDOWN(R) for Type 2 Diabetes

Boston Therapeutics, Inc. has initiated a Phase IIb clinical study to assess the efficacy and safety of SUGARDOWN(R) in 24 patients with Type 2 diabetes taking metformin. The study, SD-002, is being conducted by Accumed Research Associates in Garden City, NY under the direction of Principal Investigator Mitchell D. Efros, MD, FACS. SUGARDOWN(R) is Boston Therapeutics' (BTI) currently marketed dietary supplement that is intended to support healthy blood sugar. Previous clinical studies have indicated that SUGARDOWN(R) can maintain healthy glucose levels even after meals when sugar tends to spike. The five-week, randomized, double-blind Phase IIb study is designed to assess the safety and efficacy of SUGARDOWN(R) in two different doses versus placebo on serum glucose levels after meals in 24 subjects with Type 2 diabetes treated with metformin alone. The primary endpoint of the study is postprandial serum glucose area under the curve; secondary endpoints are peak postprandial serum glucose, time to peak postprandial serum glucose, and peak blood serum excursion at two hours from baseline.

Similar Private Companies By Industry

Company Name Region
Brighthaven Ventures, LLC United States
Vital Systems of Oklahoma, Inc. United States
Pharmaceuticals Holdings, Inc. United States
Southwood Pharmaceuticals, Inc. United States
Caribbean Pharmalogic Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Boston Therapeutics, Inc., please visit www.bostonti.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.